Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
SkinJect, Inc.
The Methodist Hospital Research Institute
Sotio Biotech Inc.
Dana-Farber Cancer Institute
Emory University
National Institutes of Health Clinical Center (CC)
Genzada Pharmaceuticals USA, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Kezar Life Sciences, Inc.
Pfizer
National Cancer Institute (NCI)
Hoffmann-La Roche
MacroGenics
Herlev Hospital
University of California, San Diego
Senhwa Biosciences, Inc.
Thomas Jefferson University
Shattuck Labs, Inc.
GlaxoSmithKline
LEO Pharma
Merck Sharp & Dohme LLC
BerGenBio ASA
Altor BioScience
University of Pennsylvania
Wright State University
Yale University
Karyopharm Therapeutics Inc
Pfizer
Biofrontera Bioscience GmbH
National Cancer Institute (NCI)
Pfizer
Istari Oncology, Inc.
Pierre Fabre Medicament
National Cancer Institute (NCI)
TuHURA Biosciences, Inc.
Pfizer
Pierre Fabre Medicament
ADC Therapeutics S.A.
Parker Institute for Cancer Immunotherapy
Merck Sharp & Dohme LLC
Pfizer
Bristol-Myers Squibb
Pfizer
Eli Lilly and Company
Eisai Inc.
Takeda
Stanford University
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey